PRMT5 and breast carcinoma: Inhibition of PRMT5 blocked the G1-to-S cell cycle transition in ER+/RBKO breast cancer cells and other cancer cells with natural loss-of-function alterations of RB1. Of relevance to our results, AbuHammad et al. recently reported that PRMT5 is an indirect target of CDK4 and is required for the sensitivity of RB-competent melanoma cells to palbociclib46.